The binding of VEGF-A with VEGFR-2 represents the most effective inducer of endothelial cell migration and proliferation and for this reason, the VEGF-A/VEGFR-2 axis is the gold target in current anti-angiogenic therapy for cancer. The gene discussed is VEGFA; the disease is cancer.